Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Preferred Stock Liabilities (2018 - 2021)

X4 Pharmaceuticals' Preferred Stock Liabilities history spans 2 years, with the latest figure at $1.9 million for Q2 2021.

  • For Q2 2021, Preferred Stock Liabilities changed N/A year-over-year to $1.9 million; the TTM value through Jun 2021 reached $1.9 million, changed N/A, while the annual FY2018 figure was $64.7 million, N/A changed from the prior year.
  • Preferred Stock Liabilities reached $1.9 million in Q2 2021 per XFOR's latest filing, roughly flat from $1.9 million in the prior quarter.
  • In the past five years, Preferred Stock Liabilities ranged from a high of $64.7 million in Q3 2018 to a low of $1.9 million in Q1 2021.